The CUB domain-containing protein-1 (CDCP1) is a transmembrane molecule that has recently been implicated in cancer progression. In this study we have established a novel mechanism for initiation of CDCP1-mediated signaling in vivo and demonstrated that specific 135-70-kDa processing of cell-surface CDCP1 by extracellular serine proteases is a prerequisite for CDCP1-dependent survival of cancer cells during metastasis. The in vivo cleavage of CDCP1 triggers a survival program involving recruitment of Src and PKCd, Src-mediated phosphorylation of cell-surface-retained 70-kDa CDCP1, activation of Akt and suppression of PARP1-induced apoptosis. We demonstrate in vivo that phosphorylated Src, PKCd and Akt all constitute activated elements of a CDCP1-signaling axis during tissue colonization of tumor cells. Preventing in vivo cleavage of CDCP1 with unique anti-CDCP1 antibodies, serine protease inhibitors or genetic modulation of the cleavage site in the CDCP1 molecule completely abrogated survival signaling associated with the 70-kDa CDCP1, and induced PARP1 cleavage and PARP1-mediated apoptosis, ultimately resulting in substantial inhibition of tissue colonization by tumor cells. The lack of CDCP1 cleavage in the lung tissue of plasminogen-knockout mice along with a coordinated reduction in tumor cell survival in a lung retention model, and importantly rescue of both by in vivo supplied plasmin, indicated that plasmin is the crucial serine protease executing in vivo cleavage of cell-surface CDCP1 during early stages of lung colonization. Together, our findings indicate that in vivo blocking of CDCP1 cleavage upstream from CDCP1-induced pro-survival signaling provides a potential mechanism for therapeutic intervention into metastatic disease.
The CUB domain-containing protein-1 (CDCP1) is a transmembrane molecule that has recently been implicated in cancer progression. In this study we have established a novel mechanism for initiation of CDCP1-mediated signaling in vivo and demonstrated that specific 135-70-kDa processing of cell-surface CDCP1 by extracellular serine proteases is a prerequisite for CDCP1-dependent survival of cancer cells during metastasis. The in vivo cleavage of CDCP1 triggers a survival program involving recruitment of Src and PKCd, Src-mediated phosphorylation of cell-surface-retained 70-kDa CDCP1, activation of Akt and suppression of PARP1-induced apoptosis. We demonstrate in vivo that phosphorylated Src, PKCd and Akt all constitute activated elements of a CDCP1-signaling axis during tissue colonization of tumor cells. Preventing in vivo cleavage of CDCP1 with unique anti-CDCP1 antibodies, serine protease inhibitors or genetic modulation of the cleavage site in the CDCP1 molecule completely abrogated survival signaling associated with the 70-kDa CDCP1, and induced PARP1 cleavage and PARP1-mediated apoptosis, ultimately resulting in substantial inhibition of tissue colonization by tumor cells. The lack of CDCP1 cleavage in the lung tissue of plasminogen-knockout mice along with a coordinated reduction in tumor cell survival in a lung retention model, and importantly rescue of both by in vivo supplied plasmin, indicated that plasmin is the crucialIntroduction During the last decade, the search for distinct molecules associated with high risk of tumor metastasis has pointed to the CUB domain-containing protein-1 (CDCP1) as a cancer-promoting molecule. CDCP1 is a transmembrane glycoprotein, high expression levels of which have been associated with cancers of colon, breast, prostate, stomach, lung, kidney, pancreas and skin . Positive staining for CDCP1 correlates inversely with disease-free survival in patients (Awakura et al., 2008; Miyazawa et al., 2010; Razorenova et al., 2011) . Enhanced expression of CDCP1 in multiple cancer types makes it an attractive prognostic marker and a putative therapeutic target.
In both mouse and chick embryo models, human tumor cells expressing elevated levels of CDCP1 showed increased levels of spontaneous and experimental metastasis compared with their counterparts with reduced or no expression of CDCP1. Thus, de novo expression of CDCP1 in CDCP1-negative cervical carcinoma HeLa cells dramatically increased their potential to colonize lungs, brain and ovaries after intravenous (i.v.) inoculations into immunodeficient mice . Furthermore, the metastatic potential of human lung carcinoma and melanoma cells correlated well with their levels of CDCP1 expression, and knockdown of CDCP1 by RNA interference resulted in a dramatic inhibition of lung colonization (Uekita et al., 2007; Liu et al., 2011) . RNA interference-induced loss of CDCP1 also suppressed the metastatic spread of aggressive human gastric carcinoma cells in both experimental and spontaneous metastasis models (Uekita et al., 2008) . Dissemination of HeLa cells, transfected with CDCP1, and prostate carcinoma PC-hi/diss cells, naturally expressing CDCP1, were also significantly inhibited by unique functionblocking anti-CDCP1 monoclonal antibodies (mAbs) .
In vivo findings have suggested that CDCP1 might function as an anti-apoptotic molecule facilitating survival of tumor cells (Uekita et al., 2008; Deryugina et al., 2009) . However, the mechanisms underlying CDCP1 functionality during tumor cell spontaneous metastasis and organ colonization remained unclear. Some evidence in favor of a pro-survival role of CDCP1 has been provided by a few in vitro studies demonstrating that CDCP1 mediates anoikis resistance of tumor cells through signal transduction involving Src-family kinases and protein kinase Cd (PKCd) (Uekita et al., 2007) . PKCd, an apoptosis-related molecule, is recruited to the Tyr-762 residue in the C-terminal domain of CDCP1, where it is phosphorylated in an Src-dependent manner (Benes et al., 2005) . In cell culture systems, CDCP1-associated Src and PKCd appeared to regulate the migration and invasion of tumor cells (Miyazawa et al., 2010; Benes et al., 2011; Razorenova et al., 2011; Spassov et al., 2011b; Wortmann et al., 2011) . It is unknown however, what initially triggers CDCP1-dependent signaling in vivo during the metastatic journey of tumor cells in a live organism. In addition, it has never been validated whether CDCP1 actually induces a survival program in vivo and whether this CDCP1-induced cascade involves the same signaling molecules that have been suggested by in vitro studies. Furthermore, the nature of the prosurvival elements downstream from the CDCP1/Src/ PKCd cascade operating in vivo also has not been resolved.
CDCP1 is a type-I, single-pass, transmembrane protein containing three CUB domains and multiple glycosylation sites . At the cell surface, CDCP1 can be present in two forms, namely, the fulllength 135-kDa form and a truncated 70-kDa form (Hooper et al., 2003; Deryugina et al., 2009) , indicated, respectively, as the 140-kDa and 80/85-kDa species in other studies (Brown et al., 2004; Bhatt et al., 2005) . In cultured tumor cells, the 70-kDa CDCP1 is generated by a limited proteolysis performed by trypsin, matriptase and plasmin, and occurs at two sites, Arg-368 and Lys-369 (He et al., 2010) . Recently it was shown that proteolytic processing of CDCP1 in vitro was accompanied by recruitment of Src and PKCd to the phosphorylated 70-kDa CDCP1 fragment (He et al., 2010) . However, whether or not the 135-70-kDa cleavage of CDCP1 occurs in vivo and if so, which endogenous proteases are responsible for generation of the 70-kDa form of CDCP1 has not been established. It also remained unclear whether the cleavage of CDCP1 has any functional role in vivo during tumor cell metastasis. Therefore, in this study we sought to establish whether proteolytic processing of tumor cell CDCP1 occurs in live animals and whether it triggers phosphorylation-dependent signaling resulting in the CDCP1 cleavage-induced pro-survival program during metastatic colonization. By using several independent approaches, we also aimed to identify protease(s) cleaving CDCP1 in vivo; discriminate distinct stage(s) of the metastatic cascade when CDCP1 processing occurs; and elucidate active signaling elements of the in vivo survival axis induced by CDCP1 cleavage.
Results
Proteolytic processing of CDCP1 in vivo facilitates tumor cell colonization The functional role of CDCP1 cleavage in tumor cell colonization was initially analyzed in transformed human embryonic kidney cells, HEK-293, which are devoid of CDCP1, making it an attractive choice for de novo expression of CDCP1. Parental HEK-293 cells were transfected with wild-type CDCP1 (HEK-CDCP1-WT) or vector control (HEK-VC) cDNA constructs, and differential expression of CDCP1 was confirmed by fluorescence-activated cell sorting (Supplementary Figure S1 ). Western blot analysis demonstrated no detectable CDCP1 in HEK-VC cells and expression of exclusively the full-length 135-kDa CDCP1 in non-enzymatically passaged HEK-CDCP1-WT cells (Figure 1a) .
In an experimental metastasis model, intravenously inoculated HEK-CDCP1-WT cells showed a four-fold increase in the colonization levels of chick embryo chorioallantoic membrane (CAM) compared with CDCP1-negative HEK-VC cells (Figure 1b, graph) . To investigate the biochemical status of tumor cell CDCP1 in vivo, the CAM tissue was analyzed at early and late time points. Western blot analysis confirmed the presence of CDCP1 only in embryos inoculated with HEK-CDCP1-WT cells (Figure 1b, blot) . At 2 h, when the majority of intravenously inoculated cells are arrested in the CAM vasculature, CDCP1 was detected exclusively as the 135-kDa CDCP1 form. By contrast, at 120 h, CDCP1 was found only as the 70-kDa form (Figure 1b, blot) , pointing to efficient and persistent in vivo cleavage. Detailed timecourse analysis of CAM colonization indicated progressive loss of the full-length 135-kDa form of CDCP1 and accumulation of the 70-kDa cleavage species between 4 and 8 h after cell inoculation, with complete conversion of CDCP1 to the 70-kDa form by 96 h (Figure 1c) .
To analyze mechanistically whether in vivo cleavage of CDCP1 functionally regulates tumor cell colonization, we either triggered or inhibited CDCP1 processing in HEK cell transfectants. First, we demonstrated in vitro that serine proteases, including trypsin, matriptase and plasmin, induced the 135-70-kDa cleavage of CDCP1 in HEK-CDCP1-WT, whereas matrix metalloproteinases (MMPs), for example, MMP-1, MMP-3 and MMP-9, failed to process CDCP1 (Figure 1d ). Related to the susceptibility of CDCP1 to serine proteases, we confirmed that in vitro 135-70-kDa processing of CDCP1 by trypsin was sensitive to aprotinin, a potent serine protease inhibitor (Figure 1e ). Second, we transfected HEK-293 cells with the CDCP1 construct, harboring genetically modified R368A-K369A residues, CDCP1-DM, rendering this double mutant of CDCP1 uncleavable (He et al., 2010) . The in vitro 135-70-kDa proteolytic cleavage of CDCP1 by the tested serine proteases, namely trypsin, matriptase and plasmin, was completely prevented in the stably transfected HEK-CDCP1-DM cells (Figure 1e and Supplementary Figure  S1d) . Furthermore, our previously reported metastasisblocking anti-CDCP1 antibodies, mAb 41-2 and mAb 10-D7 , both completely abrogated trypsin-induced cleavage of CDCP1 in HEK-CDCP1-WT cells in vitro (Figure 1f) . Therefore, these mAbs can be used as a specific and efficient tool to prevent processing of wild-type CDCP1 in live animals, especially in chick embryos where administered antibodies can be retained in circulation for several days (Supplementary Figure S2) .
In the chick embryo experimental metastasis model, the levels of CAM colonization were inhibited by 75-85% if HEK-CDCP1-WT cells were injected along with mAb 10-D7 or aprotinin, or if the embryos were injected with HEK-CDCP1-DM cells expressing uncleavable CDCP1 (Figure 2a, graph) . Indicating a functional importance of CDCP1 cleavage in colonization, the expression of uncleavable CDCP1 mutant in HEK-CDCP1-DM cells as well as the inhibitory effects of mAb 10-D7 and aprotinin on HEK-CDCP1-WT cells directly correlated with the retention of the full-length 135-kDa CDCP1 in the CAM tissue and complete lack of the cleaved 70-kDa CDCP1 (Figure 2a, blot) .
To verify whether de novo expression of CDCP1-WT or CDCP1-DM, or treatment of HEK-CDCP1-WT cells with an anti-CDCP1 mAb or a CDCP1-cleaving protease, might have affected the rates of cell proliferation and therefore contribute to differential levels of tissue colonization, we analyzed the proliferation rates of HEK cells in conventional two-dimensional cultures. No significant changes in cell morphology and proliferation potential were observed because of modulation of CDCP1 levels, presence of anti-CDCP1 mAb or treatment with plasmin (Supplementary Figures S3a, S4a and S4c) , thereby excluding proliferation from the mechanisms responsible for the limited CAM colonization potential documented in Figure 2a .
Affirming that functionally important cleavage of CDCP1 occurs within the first hours after cell injections, 24 and 48-h delays in the treatment of embryos with mAb 10-D7 or aprotinin resulted in almost complete loss of the inhibitory effects of the inoculated compounds on CAM colonization and the coordinated presence of cleaved CDCP1 (Figure 2b ).
These in vivo findings not only indicate a prometastatic role for CDCP1, but together they strongly implicate an early cleavage of CDCP1 by an undefined serine protease in conferring tumor cells with high colonization potential.
In vivo proteolytic cleavage of cell-surface CDCP1 induces tyrosine phosphorylation signaling during tissue colonization The dependence of high colonization potential of HEK-CDCP1 cells on the cleavage of CDCP1 suggested a link to activation of cell survival programs. To investigate this notion, embryos were inoculated with HEK-CDCP1-WT or HEK-CDCP1-DM cells along with control IgG, mAb 10-D7 or aprotinin (Figure 3 ). The CAM tissue was harvested at day 5 and lysed, and CDCP1 was immunoprecipitated with mAb 41-2 and probed for tyrosine phosphorylation, and for the presence and phosphorylation status of co-precipitated CDCP1 cleavage induces survival signaling and colonization B Casar et al Src and PKCd. In normal IgG-treated embryos, wildtype CDCP1 was identified almost exclusively as the 70-kDa form, whereas the 135-kDa CDCP1 was the major form in the embryos treated with mAb 10-D7 or aprotinin ( Figure 3a , upper panel). Probing the immunoprecipitated proteins for tyrosine phosphorylation demonstrated that only 70-kDa CDCP1-WT from control embryos was tyrosine phosphorylated, while uncleaved 135-kDa CDCP1-WT from both mAb 10-D7-and aprotinin-treated embryos was almost completely devoid of tyrosine phosphorylation (Figure 3a) . Importantly, tyrosine-phosphorylated 70-kDa CDCP1 was associated with Src and PKCd as indicated by their co-precipitation. However, no Src or PKCd was detected in the immunoprecipitates when the in vivo proteolysis of CDCP1 was blocked by either mAb 10-D7 or aprotinin, and CDCP1 was represented by its full-length 135-kDa form. Furthermore, Src and PKCd, associated with the 70-kDa CDCP1, were both tyrosinephosphorylated, indicating their functional activity (Figure 3a) . In contrast to the cleaved CDCP1-WT in control embryos, no cleavage of CDCP1, and little or no tyrosine phosphorylation of the 135-kDa CDCP1 were detected in embryos injected with HEK-CDCP1-DM cells (Figure 3b) . Correspondingly, the lack of CDCP1 cleavage and tyrosine phosphorylation in HEK-CDCP1-DM cells in vivo was accompanied by the lack of recruitment of Src and PKCd to the full-length, uncleavable CDCP1 (Figure 3b ). These in vivo findings demonstrate tyrosine phosphorylation of the 70-kDa CDCP1 during tumor cell colonization in a live animal model and establish that CDCP1-associated Src and PKCd are phosphorylated signal elements associated with only the cleaved, phosphorylated 70-kDa CDCP1, but not with the uncleaved molecule.
We hypothesized that in vivo cleavage of the 135-kDa CDCP1 and the 70-kDa CDCP1/Src/PKCd signaling axis would lead directly to downstream induction of pro-survival molecules, thereby facilitating tumor cell colonization. Reciprocally, inhibition of CDCP1 cleavage and lack of Src/PKCd phosphotyrosine signaling might facilitate activation of a tumor cell apoptotic program in vivo. To verify these notions, CAM tissue was probed for activation of Akt, a pro-survival signaling molecule (Altomare et al., 2004; Zhang et al., 2009) , and also for cleavage of PARP1, a substrate of activated executioner caspases (Chaitanya et al., 2010) . Importantly, the phosphorylated Akt was identified only in the embryos inoculated with HEK-CDCP1-WT cells and control IgG (Figure 3c ), concomitant with the induced appearance of the 70-kDa CDCP1/Src/PKCd complex ( Figure 3a ). By contrast, phosphorylated Akt was not found under conditions where CDCP1 cleavage was prevented either by the function-blocking anti-CDCP1 mAb 10-D7, the serine protease inhibitor aprotinin or mutagenesis of the cleavage site ( Figures  3c and d) . Coordinately with the lack of activated Akt, the cleaved 89-kDa PARP1 was identified under conditions where the 135-kDa CDCP1 was not cleaved (Figures 3c and d) , indicating activation of a caspasemediated pro-apoptotic program. No cleaved PARP1 was detected when generation of tyrosine phosphorylated 70-kDa CDCP1/Src/PKCd complex and phosphorylation of Akt were observed (Figure 3c ), further pointing to cleaved CDCP1 as inducing pro-survival signaling in vivo.
As biochemical analyses of immunoprecipitated CDCP1 required reduction of tissue samples prior to sodium dodecyl sulfate-PAGE, we investigated whether proteolysis-induced cleavage of CDCP1 in HEK- Figure 2 Proteolytic cleavage of CDCP1 in vivo yields high levels of cell colonization. (a) High levels of CAM colonization depend on CDCP1 cleavage in vivo. HEK-CDCP1-WT or HEK-CDCP1-DM cells were inoculated intravenously into chick embryos along with control IgG, anti-CDCP1 mAb 10-D7 or aprotinin (Apro). The levels of CAM colonization and cleavage status of CDCP1 were analyzed at day 5 by Alu-qPCR and western blotting, respectively. The bars are the means±s.e.m. determined in two independent combined experiments using from 13 to 15 embryos per variant. Statistical analyses were performed in comparison with IgG-treated HEK-CDCP1-WT group. **Po0.005 and ***Po0.001 (two-tailed Student's t-test). (b) CDCP1 cleavage contributes to high levels of CAM colonization during early stages of experimental metastasis. HEK-CDCP1-WT cells were inoculated intravenously into chick embryos along with control IgG, anti-CDCP1 mAb 10-D7 or aprotinin (Apro) either immediately or with delays of 24 or 48 h. The levels of CAM colonization and cleavage status of CDCP1 were analyzed at day 5 by Alu-qPCR and western blotting, respectively. The bars are the means±s.e.m. from one representative experiment using from 6 to 12 embryos per time point/treatment. *Po0.05 and **Po0.005 (two-tailed Student's t-test). Proteins, co-precipitated with CDCP1 were also analyzed for the presence and phosphorylation status (p) of PKCd and Src, both of which were identified in coordination only with the cleaved 70-kDa CDCP1. Specificity of CDCP1 precipitation was confirmed by using control mouse IgG. Probing for mouse IgG was performed as a loading control. (b) Lack of CDCP1 cleavage correlates with absence of CDCP1 phosphorylation and phosphorylation signaling. Chick embryos were inoculated with HEK-CDCP1-DM cells along with control IgG, anti-CDCP1 mAb 10-D7 or aprotinin. The cleavage status and phosphorylation status of CDCP1, and the presence of CDCP1-associated PKCd and Src, were analyzed as described in panel a. (c) In vivo activation of Akt and inhibition of PARP1 cleavage both depend on the cleavage of CDCP1. Total lysates of CAM tissue harvested from embryos inoculated with HEK-CDCP1-WT cells were analyzed at day 5 for total Akt, Akt phosphorylation (pAkt) and specific PARP1 cleavage (indicated by the presence of the 89-kDa fragment). (d) Inhibition of Akt phosphorylation and induction of PARP1 cleavage by abrogation of CDCP1 cleavage. Chick embryos were inoculated with HEK-CDCP1-DM cells and CAM tissue analyzed at day 5 as described in panel c.
CDCP1 cleavage induces survival signaling and colonization
B Casar et al tion of cleaved CDCP1 is unlikely a mechanism responsible for recruitment of phosphorylated Src and PKCd, and initiation of Akt-involving pro-survival cascade.
Proteolytic cleavage of naturally expressed CDCP1 facilitates colonization of human carcinoma cells We next validated the functional contribution of CDCP1, its proteolytic processing in vivo and survival signaling induced by cleavage of CDCP1 during metastatic dissemination of human prostate PC-hi/diss carcinoma cells, which unlike the HEK cells, naturally express CDCP1. Expression of CDCP1 in PC-hi/diss cells was downregulated with a specific shRNA construct (shCDCP1), whereas a non-silencing shRNA (shNS) was used to generate control cells. When passaged non-enzymatically, the control PC-shNS cells present almost exclusively the full-length 135-kDa CDCP1, although a small portion of the 70-kDa species of CDCP1 can also be detected, while both forms are substantially diminished in the PC-sh CDCP1 cells ( Figure 4a ).
We initially verified in vitro that the CDCP1 deficiency in PC-shCDCP1 cells as well as treatment of control PCshNS cells with the mAb 10-D7 did not affect significantly their rates of proliferation or morphology in two-dimensional cultures (Supplementary Figures S3b and S4b) . However, CDCP1 deficiency caused a substantial reduction of colony formation in soft agar (Supplementary Figure S6) , further suggesting a link between CDCP1, CDCP1 cleavage and activation of tumor cell survival mechanisms. Next, we analyzed the colonization behavior of PC-hi/diss cells with respect to the level of CDCP1 expression by live-cell imaging of fluorescently labeled tumor cells in the CAM tissue. Twenty-four hours after cell inoculations, control PCshNS cells appeared to extravasate normally from the terminal CAM capillaries (Figure 4b Figure 4c ). Substantial inhibition of CAM and liver colonization was also achieved when control PC-shNS cells were inoculated with either mAb 10-D7 or aprotinin (Figure 4c ). The lack of CDCP1 processing in the tissues from these embryos was confirmed by western blot analysis, which indicated that in embryos treated with inhibitors of CDCP1 cleavage, CDCP1 was represented exclusively by the full-length 135-kDa form, in contrast to the 70-kDa CDCP1 identified in the CAM tissue of the embryos treated with control IgG (Figure 4d ). Under these in vivo conditions, CDCP1 was undetected in the CAM of embryos inoculated with the shCDCP1-transfected PC-hi/diss cells, likely attributable to both low levels of downregulated CDCP1 expression and, correspondingly, the low colonization capability of PCshCDCP1 cells (Figure 4c ). The sensitivity of CDCP1 cleavage in PC-shNS cells to mAb 10-D7 and aprotinin, and the strong correlation between the appearance of 70-kDa CDCP1 and the enhanced levels of tumor cell colonization, suggested that in vivo CDCP1 processing might also be associated with the induction of survival programs. In agreement, in vivo probing for Akt pro-survival signaling demonstrated the presence of phosphorylated Akt in the CAM tissue only from embryos inoculated with control PCshNS cells and control IgG, that is, where distinctive CDCP1 cleavage was manifested (Figure 4d ). Correspondingly, in vivo phosphorylation of Akt was almost completely abrogated when CDCP1 cleavage was inhibited by mAb 10-D7 or aprotinin, accompanied by a coordinate appearance of cleaved PARP1. Similar reciprocal changes in Akt activation and PARP1 cleavage were observed when CDCP1 expression was reduced to levels undetectable in vivo in PC-shCDCP1 cells (Figure 4d ). Together, these findings validate the functional role of CDCP1 in the colonization of prostate carcinoma cells and strongly implicate the cleavage of CDCP1 in the induction of survival signaling required for high levels of metastasis.
Src-dependent phosphorylation of cleaved CDCP1 is required for CDCP1-mediated organ colonization To investigate whether Src activation is involved in survival signaling mediated by proteolytically cleaved 70-kDa CDCP1, HEK-CDCP1-WT cells were inoculated intravenously along with dasatinib (BMS354825), a potent inhibitor of Src-family kinases (Nam et al., 2005) . Both CAM and liver colonization were inhibited by dasatinib to 10-20% of the corresponding levels observed in vehicle-treated embryos (Figure 5a ). Moreover, dasatinib reduced the levels of HEK-CDCP1-WT colonization almost to the levels shown by control HEK-VEC cells (Supplementary Figure S7a) , thereby indicating that overall CDCP1-induced signaling operates mainly through an Src-dependent cascade during organ and tissue colonization.
Analysis of CAM tissue demonstrated that CDCP1 in vivo was represented by the cleaved 70-kDa form under both dasatinib and vehicle treatment conditions. However, dasatinib almost completely abrogated the phosphorylation of the cleaved CDCP1 (Figure 5b ), pointing out that Src kinase activity is required for CDCP1 phosphorylation. Surprisingly, total levels of CDCP1-associated Src were similar in both vehicle control-and inhibitor-treated animals (Figure 5b) , indicating a phosphorylation-independent binding of Src to the cleaved CDCP1. These in vivo data demonstrate for the first time that non-activated and activated Src are equally capable of binding to the 70-kDa CDCP1, but the kinase activity of tyrosine-phosphorylated Src is required for tyrosine phosphorylation of the cleaved CDCP1.
We further established that the Src-mediated signaling induced by proteolytic processing of naturally expressed CDCP1 also confers tumor cells with high levels of colonization potential. Thus, treatment with dasatinib reduced by more than 95% the levels of CAM and liver colonization by PC-hi/diss cells (Figure 5c ). Western blot analysis of CAM tissue confirmed that CDCP1 was cleaved in both vehicle-and dasatinib-treated embryos, but indicated that dasatinib treatment resulted in a significantly reduced phosphorylation of Src associated with CDCP1. This lack of Src phosphorylation was accompanied by almost completely abrogated tyrosine phosphorylation of 70-kDa CDCP1 despite the similar amounts of Src protein co-precipitated with CDCP1 isolated from both groups of embryos (Figure 5d ).
If a Src-mediated pro-survival program is linked to CDCP1 cleavage, which is initiated within the first hours after cell inoculation (Figure 1c) , then a delay in the delivery of dasatinib should significantly reduce the effects of Src kinase inhibition on colonization capacity. This notion was verified when the embryos inoculated with HEK-CDCP1-WT cells received dasatinib with the cells or 24 h after cell inoculation (Supplementary Figure  S7b) . The 24-h delay in dasatinib administration resulted in significant reduction of inhibitor effects on tumor cell colonization, demonstrating that the survival program associated with CDCP1 cleavage requires Src activity and is triggered at an early stage of tissue and organ colonization when selection pressure between tumor cell survival and apoptosis is critical.
Together, these data indicate that CDCP1-mediated survival signaling in vivo involves Src-dependent phosphorylation of 70-kDa CDCP1, Akt activation and suppression of PARP1 cleavage, all of which are linked directly to the proteolysis-induced cleavage of CDCP1 expressed on the surface of bona fide carcinoma cells or transformed cells.
In vivo proteolytic cleavage of CDCP1 contributes to high levels of lung colonization in mice through activation of Akt pro-survival signaling The in vivo proteolytic processing of CDCP1 and its prosurvival role in tumor cell dissemination were further validated in a mouse lung colonization model. We first demonstrated that cleavage of CDCP1 strongly facilitated retention of CDCP1-positive cells in the pulmon- (Figure 6a ). These diminished levels of lung retention were comparable to those shown by HEK-CDCP1-DM cells expressing uncleavable CDCP1 (Figure 6a ). Furthermore, both CDCP1-DM and CDCP1-WT from mAb 10-D7-treated mice were present in the lung tissue as the non-processed, fulllength, 135-kDa CDCP1, in contrast to the cleaved 70-kDa CDCP1 identified in the lung tissue of mice inoculated with HEK-CDCP1-WT cells and control IgG (Figure 6b ). In a similar manner, lung retention of PC-hi/diss carcinoma cells was inhibited by 85% when the cells were inoculated with the CDCP1 cleavageinhibitory mAb 10-D7 (Figure 6c ). To rule out the possibility that the inhibitory effects of the anti-CDCP1 mAb 10-D7 on the 24-h lung retention of inoculated cells could be attributed to a possible inhibition of initial cell arrest in the pulmonary vasculature, we quantified the number of PC-hi/diss and HEK-CDCP1-WT cells in the lungs 2 h after i.v. inoculation and demonstrated that at the early 2-h time point, when no cleavage of CDCP1 was observed in the mouse lung, these numbers were nearly identical (Figure 6d ). However, mAb 10-D7-mediated diminishment of PC-hi/diss lung retention at 24 h was consistent with the lack of CDCP1 cleavage in vivo, as demonstrated by western blotting of the lung tissue harvested 24 h after cell inoculations (Figure 6e ). Of critical importance, these mAb 10-D7-induced diminishments of CDCP1 cleavage and PC-hi/diss lung retention were accompanied correspondingly by reduced Akt activation and, reciprocally, by the appearance of 89-kDa cleaved PARP1 (Figure 6e ).
To analyze how proteolytic cleavage of CDCP1 affects long-term colonization, immunodeficient mice were inoculated with PC-hi/diss cells either with control IgG or mAb 10-D7 (Figure 7a ). Four weeks later, quantitative analysis of recipient tissues by quantitative PCR amplifying human specific Alu repeats (Alu-qPCR) indicated that treatment with mAb 10-D7 dramatically reduced the levels of lung, liver and brain colonization by PC-hi/diss cells (Figure 7a ), consistent with previously shown dependence of 24-h lung retention on the Figure  S8a) . By contrast, 10-D7-treated recipients failed to present any detectable human tumor cell colonization (Figure 7b, right) .
As an alternative approach, immunodeficient mice were inoculated with HEK-CDCP1 cells expressing wildtype or the cleavage-resistant mutant of CDCP1. As quantitatively presented in Figure 7c , expression of noncleavable CDCP1 correlated with very low potential of HEK-CDCP1-DM cells to colonize lungs, liver and brain as compared with their wild-type counterparts expressing cleavable CDCP1. Correspondingly, histological and immunohistochemical analyses of lung tissue from mice inoculated with HEK cells expressing cleavable CDCP1 readily identified colonies of human cells positive for CDCP1 and human CD44, whereas the lack of cleavable CDCP1 in HEK-CDCP1-DM cells was manifested by the lack of microscopically identifiable lung colonization (Figure 7d and Supplementary Figure S8b) .
Collectively, these findings demonstrate that cleavage of CDCP1 is critically important for the ability of CDCP1-expressing cells to initially and continually manifest their colonization potential in both avian and mammalian live animal models. Plasmin is a major serine protease responsible for proteolytic cleavage of CDCP1 in vivo The coordinated inhibitory effects of aprotinin on the 135-70-kDa cleavage of CDCP1 and metastatic colonization of human tumor cells suggested that plasmin, an endogenous aprotinin-sensitive and potentially abundant serine protease, could be responsible for proteolytic processing of CDCP1 in vivo. Thus, HEK-CDCP-WT cells were inoculated into wild-type mice or knockout (KO) mice genetically deficient in plasminogen, the precursor of plasmin. At 24 h, the lung retention of HEK-CDCP1-WT cells was substantially lower in the plasminogen-KO mice (Figure 8a ), concomitant with a complete lack of CDCP1 cleavage in the lungs of plasminogen-KO mice (Figure 8b ). Furthermore, the detection of plasmin activity in wild-type mice and the complete lack thereof in the plasma in plasminogen-KO mice (Figure 8c ) corresponded precisely with the cleaved or native status of the CDCP1 in the lung-retained cells. Reduced levels of lung retention and the absence of 70-kDa CDCP1 in plasminogen-KO mice were accompanied by a substantial reduction in the levels of Akt activation/phosphorylation and, reciprocally, by the induction of PARP1 cleavage (Figure 8b ), indicating an inhibition of survival signaling and activation of a caspase-mediated pro-apoptotic program when CDCP1 is not cleaved by plasmin. That plasmin is the serine protease responsible for in vivo CDCP1 processing was validated in a rescue experiment in which plasminogen-KO mice were intravenously supplemented with purified plasmin 1 h after cell inoculations. Not only did supplementation with plasmin elevate the levels of plasmin activity in the plasma of plasminogen-KO mice to those observed in the wild-type control (Figure 8c ), but, importantly, it also fully restored the 24-h lung retention levels of HEK-CDCP1-WT cells (Figure 8d ) as well as a full processing of 135-kDa CDCP1 into the 70-kDa species (Figure 8e ), further indicating that plasmin is a major endogenous serine protease responsible for CDCP1 cleavage in vivo.
Discussion
The present study was undertaken to investigate in vivo the functional role of limited, 135-70-kDa proteolysis of CDCP1 and cleavage-induced activation of CDCP1 for metastatic colonization of human cancer cells. This unanswered issue was elucidated in avian and mammalian models of experimental metastasis using a highdisseminating variant of human PC-3 prostate carcinoma, PC3-hi/diss, naturally expressing CDCP1, and also HEK-293 cells, transfected with wild-type CDCP1 or a non-cleavable R368A-K369A mutant of CDCP1. Using HEK-293 cells as a model devoid of CDCP1, we have demonstrated that de novo expression of CDCP1 confers transfected cells with high colonization potential both in chick embryos and mice. Reciprocally, downregulation of naturally expressed CDCP1 by RNA interference substantially reduced the ability of prostate carcinoma PC-hi/diss cells to colonize the CAM and liver in the chick embryo model. Thus, high levels of CDCP1 correlated positively with the enhanced colonization ability of tumor cells, affirming that CDCP1 is a critical cell-surface transmembrane molecule, which regulates the metastatic potential of cancer cells. Importantly, our present investigation has also demonstrated that cell-surface CDCP1 should be first cleaved to become functionally active, generating CDCP1-dependent pro-metastatic signaling and regulating the metastatic outcome.
Limited proteolysis involving either shedding of extracellular domain(s) or intrinsic cleavage of a peptide bond represents a distinctive mode of functional regulation for a number of plasma membrane-anchored receptors. Thus, protease-activated receptors are activated by proteolytic cleavage and release of a tethered ligand by serine proteases (Coughlin 2000; Shi et al., 2004) . The internal cleavage of the av integrin subunit by MT1-MMP, leading to functional activation of avb3 integrin, represents an additional example of limited proteolysis of a cell-surface receptor without shedding of its extracellular domain (Deryugina et al., 2002) . In the present study, we have demonstrated that CDCP1, either naturally expressed in PC-hi/diss cells or wildtype CDCP1 expressed in HEK-293 cells, is efficiently processed in vivo from the 135-kDa full-length molecule to the 70-kDa cell-surface-retained fragment during experimental metastasis in chick embryos. In a similar manner, 135-70-kDa cleavage of CDCP1 in both cell types was evidenced in the 24-h lung retention model in mice. Furthermore, the administration of either the cleavage-blocking anti-CDCP1 mAb 10-D7 or expression of a non-cleavable CDCP1 mutant resulted in a substantial reduction of cell colonization capacity. These findings establish a direct link between the 135-70-kDa processing of CDCP1 and its functionality, and strongly implicate CDCP1 cleavage in the metastatic potential of tumor cells. Furthermore, the importance of CDCP1 cleavage in the overall tumor cell physiology is suggested by the lack of reported genetic mutations ascribed to the cleavage region of the molecule (The Catalogue of Somatic Mutations in Cancer provided by The Welcome Trust Sanger Institute at http://www.sanger.ac.uk).
Proteolytic activation of cell membrane-tethered molecules in vivo can be regulated at the levels of specificity and/or availability of enzymatically competent cleaving proteinases. Thus, CDCP1 is resistant to a number of metalloproteinases, including MMP-1, MMP-3 and MMP-9, but is highly susceptible to serine proteases such as trypsin, plasmin and matriptase, all causing 135-70-kDa CDCP1 processing in vitro demonstrated in this and other studies (Brown et al., 2004; Bhatt et al., 2005; He et al., 2010) . Several lines of evidence point to plasmin as the natural protease directly cleaving cell-surface CDCP1 in vivo. First, aprotinin, a potent inhibitor of plasmin (Landis et al., 2001) , completely abrogates in vivo CDCP1 cleavage and significantly reduces CDCP1-dependent cell colonization. Second, genetic substitution of R368-K369 residues to A368-A369, rendering CDCP1 uncleavable, is consistent with the arginine-and lysine-containing cleavage sites preferred by plasmin (Schmidt et al., 2005; Gray and Ellis, 2008) . Third, plasminogen-KO mice are completely incapable of the 135-70-kDa CDCP1 processing, which is clearly observed in the wild-type counterparts. Finally, supplementation of plasminogen-KO recipients with physiological concentrations of purified plasmin fully rescued in vivo cleavage of CDCP1 and restored the lung retention of CDCP1-expressing cells.
Related to functional activation of CDCP1 is the notion that limited proteolysis of CDCP1 in vivo occurs at a specific time point during the metastatic cascade. Our findings from experimental metastasis model in chick embryos and lung retention model in mice clearly indicate that CDCP1 cleavage is initiated soon after inoculated cells are arrested, respectively, in the chick 
inoculation of cells into WT and Plgn
À/À mice. Probing of blot was performed to determine the cleavage status of CDCP1, and the levels of activated Akt (pAkt) and cleaved 89-kDa PARP1. (c) Plasmin activity in plasma of wild type and plasminogen-deficient mice. Plasmin activity assay was measured by direct activity assay of plasma samples harvested 24 h after i.v. inoculation of HEK-CDCP1-WT cells into wild-type (WT) and plasminogen-KO mice (Plgn À/À ). Plasmin deficiency in plasminogen-KO mice was restored with purified plasmin supplemented intravenously to physiological concentrations observed in the plasma of wild-type mice. (d) The levels of human cell retention in murine lungs depend on the plasma levels of plasmin. Low levels of lung retention in plasminogen-KO mice (Plgn À/À ) are restored to the control levels of wild-type mice (WT) by purified plasmin administered 1 h after cell inoculations. Shown is one of two independent experiments each using 4 (WT) and 3 (Plgn À/À ) mice. The bars are the means ± s.e.m. *Po0.05 (twotailed Student's t-test). (e) Western blot analysis of CDCP1 in human cells retained in murine lungs. Lung tissue samples were harvested from wild-type (WT) and plasminogen-KO (Plgn À/À ) mice 24 h after inoculation of HEK-CDCP1-WT cells with or without purified plasmin as described in panel d, and analyzed for CDCP1 cleavage status by western blotting.
CDCP1 cleavage induces survival signaling and colonization B Casar et al embryo CAM or in the mouse pulmonary vasculature. In both tissues, CDCP1 cleavage was not observed during vascular arrest at the 2-h time point, but was initiated between 4 and 8 h, and can be completed within 24-72 h after cell inoculations. Further indicating relatively early cleavage of CDCP1 in vivo, a 24-h delay in the administration of cleavage inhibitors, such as, mAb 10-D7 or aprotinin, resulted in CDCP1 cleavage and high levels of CAM colonization. Collectively, our in vivo findings point out that limited proteolysis of CDCP1 by the endogenous serine protease is initiated likely during or soon after tumor cell extravasation.
An important aspect of this study is that CDCP1-mediated signaling was linked not only with the presence or expression levels of CDCP1, but associated rather strongly with cleavage of CDCP1 in vivo. We have demonstrated that processing of 135-kDa CDCP1 in live animals induces tyrosine phosphorylation of the cleaved 70-kDa form of CDCP1 concomitant with the recruitment of phosphorylated Src and PKCd to the cleaved CDCP1. Furthermore, inhibition of Src activity with dasatinib indicates that both phosphorylated and nonphosphorylated Src can efficiently bind in vivo to the generated 70-kDa CDCP1. However, the kinase activity of Src is clearly required for phosphorylation and functional activation of 70-kDa CDCP1. Therefore, cleavage of CDCP1 appears to be a prerequisite for docking of phosphorylated Src, thereby allowing activated Src to transduce downstream signals leading to high levels of tissue colonization. Although the precise mechanism(s) triggering in vivo activation of Src during different steps of the metastatic cascade, including tumor cell extravasation and colonization, have not been definitively established in the literature, our findings indicate that, without cleaved CDCP1, a substantial portion of activated Src would not have a docking platform to transduce its pro-survival signals through downstream phosphorylation of cleaved CDCP1, phosphorylation of recruited PKCd and activation of Akt.
These novel in vivo findings are in apparent contrast with some recent in vitro findings linking overexpression of CDCP1 with Src activation (Liu et al., 2011) , but support the previously shown dependence of in vitro phosphorylation of CDCP1 on activated Src (Brown et al., 2004; Benes et al., 2005; Alvares et al., 2008; Miyazawa et al., 2010; Spassov et al., 2011a, b) . In addition, we have highlighted that Src-mediated signaling in vivo should be initiated not later than 24 h after cell inoculations to promote CDCP1-dependent colonization, independently providing another support for an early signal cascade induced by CDCP1 cleavage. In view that dasatinib has been approved by the FDA as an effective and safe drug for treatment of some types of leukemia and currently is in phase-II trials for efficacy and safety in patients with advanced sarcomas and hormonerefractory prostate cancer (http://clinicaltrials.gov), our demonstration of dasatinib-inhibited PC-hi/diss colonization indicates that blocking of cleaved CDCP1 phosphorylation in prostate cancer cells can represent one of the possible critical inhibitory mechanisms of this Src kinase inhibitor.
Complementing Src/PKCd signaling evoked by CDCP1 cleavage in vivo, we also have demonstrated that the signal transduction induced by 135-70-kDa CDCP1 processing in vivo results in the downstream activation of the prosurvival effector molecule Akt and Akt-dependent tumor cell colonization. By contrast, inhibition of CDCP1 cleavage, either by the mAb 10-D7, inhibition of plasmin by aprotinin or genetic ablation of the plasmin precursor, plasminogen, ultimately leads to caspase activation and initiation of PARP1-mediated tumor cell apoptosis as a possible default mode in in vivo settings where specific CDCP1 cleavage does not occur. The relatively small amount of cleaved PARP1 detected in vivo could reflect the limited number of cells at advanced stages of apoptosis that are still retained in the colonized tissues and/or the small portion of cells that are undergoing apoptosis induced by pro-apoptotic conditions in vivo and exacerbated by blocking CDCP1 cleavage. The latter suggestion is supported by our in vitro data indicating that an anti-CDCP1 mAb enhance the rates of apoptosis initially induced by doxorubicin treatment . Furthermore, the 89-kDa PARP1 species can undergo further processing into lower molecular weight forms (Gobeil et al., 2001) , which can explain the relatively small amounts of cleaved PARP1 at a given time in vivo. While earlier investigations had indicated that the CDCP1 molecule had direct anti-apoptotic functions, our study emphasizes that it is the cleavage of CDCP1 that initiates the pro-survival program and that blocking CDCP1 cleavage enhances cell apoptosis. Correspondingly, the lack of processed 70-kDa CDCP1 is directly associated with the lack of CDCP1 survival signaling and, therefore, reduced levels of colonization.
In conclusion, our in vivo findings, summarized in Figure 9 , indicate that limited proteolytic processing of CDCP1 uniquely renders the molecule with functional activity, and that 135-70-kDa-specific cleavage of CDCP1 facilitates tumor cell survival during metastasis through the Src/PKCd/Akt signaling axis. The serine protease plasmin is a CDCP1 cleavage agonist that is necessary and sufficient for in vivo 135-70-kDa CDCP1 processing that induces CDCP1-mediated pro-survival Akt signaling. It also appears that plasmin-generated CDCP1 cleavage at the cell surface is a critical biochemical event, which is required for efficient metastatic colonization of CDCP1-expressing cells. In view of the correlations established between high levels of CDCP1 in tumors, and poor prognosis and outcome for cancer patients, specific blocking of CDCP1 processing and the ensuing CDCP1-induced signaling represents an attractive therapeutic approach to inhibit the dissemination of CDCP1-positive malignant cells. Abrogation of CDCP1 cleavage can sensitize tumor cells to caspasemediated activation of pro-apoptotic effector molecules such as PARP1, enhancing tumor cell death during metastatic spread and thus substantially reducing the levels of secondary organ colonization. The findings of this study strongly suggest that inhibition of cleavageinduced functional activation of CDCP1 might be an effective adjuvant therapy of metastatic disease upstream from the signaling axis induced by cleaved CDCP1.
Materials and methods

Reagents
The CDCP1-specific antibodies mAb 41-2 and 10-D7 were generated by subtractive immunization as described (Hooper et al., 2003; Deryugina et al., 2009) . Additional information about the antibodies and reagents used in this study can be found in the Supplementary information.
CDCP1 expression constructs and cell lines
Site-directed mutagenesis was performed in wild-type CDCP1 (CDCP1-WT) to introduce the R368A and K369A mutations, and generate a double-mutant construct (CDCP1-DM) as described by He et al. (2010) . HEK-293 cells stably transfected with the CDCP1-WT or CDCP1-DM constructs are described in detail in the Supplementary information. The highly disseminating PC-hi/diss cells were selected from the prostate carcinoma PC-3 cell line as described . To knock down CDCP1, the PC-hi/diss cells were stably transfected with the pGIPZ1shCDCP1 vector along with appropriate packaging vectors. A control pGIPZ1shNS vector was used to generate PC-hi/diss cells expressing a non-silencing shRNA. All cells were routinely passaged using an enzyme-free cell dissociation solution.
Experimental metastasis in mice All procedures involving animals were approved by the Animal Care and Use Committee of TSRI. Female athymic nude mice aged 6-8 weeks (TSRI breeding facility) were injected intravenously with 1 Â 10 6 cells. Where indicated, 50 mg of mAb 10-D7 or control mouse IgG were inoculated with cell suspensions, followed by a single 50-mg inoculation, administered intraperitoneally within 36 h. Four weeks later, the mice were killed and internal organs were harvested and analyzed by Alu-qPCR to determine the numbers of human cells or fixed in Zn-formulated formalin and processed for histological and immunohistochemical analyses.
Pulmonary tumor cell arrest and retention in mice
Wild-type or plasminogen-KO mice aged 6-8 weeks were injected through the lateral tail vein with 1 Â 10 6 cells. Where indicated, the mice received 50 mg of mAb 10-D7 or control mouse IgG, or 200 ml of 0.5 mm plasmin, at the time of cell injections. After 2 or 24 h, the mice were killed. Peripheral blood was collected into heparin-containing tubes to determine specific plasmin activity in the plasma. The lungs were excised and analyzed for the number of tumor cells arrested in the lung vasculature (2 h) or retained in the lung tissue (24 h) by humanspecific Alu-qPCR as described . The status of CDCP1 cleavage in the inoculated cells was analyzed in lung lysates by western blotting.
Experimental metastasis and live-cell imaging in chick embryos
These assays were performed as described by Deryugina et al. (2009) , and along with Alu-qPCR analysis are described in detail in the Supplementary information.
Soft agar colony formation assay, immunohistochemistry, western blot analysis, immunoprecipitation and direct plasmin activity assay These well-established procedures are described in detail in the Supplementary information.
Statistical analysis and data presentation
Data processing and statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). The levels of tissue colonization are expressed as the number of human cells determined by Alu-qPCR within 10 6 host cells and presented as means ± s.e.m. calculated from numerical data from a representative or pooled experiments. Unpaired, twotailed Student's t-test was used to determine P-values for the differences between the experimental data sets. Po0.05 was considered statistically significant.
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The authors declare no conflict of interest. Figure 9 Specific proteolytic cleavage of cell-surface CDCP1 results in the induction of Akt survival signaling in vivo. The schematic representation depicts the full-length CDCP1 molecule, containing three extracellular CUB domains, a transmembrane domain and an intracellular C-terminus. In vivo, proteolytic cleavage performed by plasmin results in the shedding of a 65-kDa ectodomain and accumulation of the 70-kDa fragment retained in the plasma membrane. The cleavage is associated with the docking of activated Src, which phosphorylates the C-terminus of the 70-kDa CDCP1 and the docking of activated (phosphorylated) PKCd. Whereas both inactive and active Src dock the cleaved CDCP1, only activated Src phosphorylates CDCP1 as the Src kinase inhibitor dasatinib prevents the activation of Src but not its association with cleaved CDCP1. Inhibition of CDCP1 cleavage in vivo by either the cleavage-blocking anti-CDCP1 mAb 10-D7, the inhibitor of serine proteases, aprotinin, or by mutagenesis of the cleavage site abrogates the phosphorylation of CDCP1, the docking of activated Src and PKCd, and induces the caspase activation and the caspase-mediated cleavage of PARP1 resulting in cell apoptosis. Conversely, the 135-70-kDa processing of CDCP1 leads to the activation of Akt and the induction of cell the survival program, resulting in high levels of tumor cell colonization.
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